VistaGen

VTGN NASDAQ
0.6097
-0.0003
-0.05%
盘后: 0.6364 +0.0267 +4.38% 16:18 08/20 EDT
开盘
0.6500
昨收
0.6100
最高
0.6600
最低
0.5900
成交量
20.93万
成交均量(3M)
25.78万
52周最高
2.440
52周最低
0.3801
换手率
0.49%
市值
2,598.72万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供VistaGen VTGN股票价格,VistaGen股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies. The Company is focused on regenerative medicine (RM) applications using blood, cartilage, heart and/or liver cells derived from hPSCs.
展开 >

最近浏览

名称
价格
涨跌幅